Triple-Negative Breast Cancer Progression and Drug Resistance in the Context of Epithelial–Mesenchymal Transition
Cancers · 12.01.2025 · 17 (2) · 228
DOI: 10.3390/cancers17020228 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 12.01.2025. Verfasst von Ewa Błaszczak und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, Medical University of Lublin, 1 Chodzki Street, 20-093 Lublin, Poland. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 250 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Univeristy of Lublin, Medical University of Lublin.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) is one of the most difficult subtypes of breast cancer to treat due to its distinct clinical and molecular characteristics. Patients with TNBC face a high recurrence rate, an increased risk of metastasis, and lower overall survival compared to other breast cancer subtypes. Despite advancements in targeted therapies, traditional chemotherapy (primarily using platinum compounds and taxanes) continues to be the standard treatment for TNBC, often with limited long-term efficacy. TNBC tumors are heterogeneous, displaying a diverse mutation profile and considerable chromosomal instability, which complicates therapeutic interventions. The development of chemoresistance in TNBC is frequently associated with the process of epithelial–mesenchymal transition (EMT), during which epithelial tumor cells acquire a mesenchymal-like phenotype. This shift enhances metastatic potential, while simultaneously reducing the effectiveness of standard chemotherapeutics. It has also been suggested that EMT plays a central role in the development of cancer stem cells. Hence, there is growing interest in exploring small-molecule inhibitors that target the EMT process as a future strategy for overcoming resistance and improving outcomes for patients with TNBC. This review focuses on the progression and drug resistance of TNBC with an emphasis on the role of EMT in these processes. We present TNBC-specific and EMT-related molecular features, key EMT protein markers, and various signaling pathways involved. We also discuss other important mechanisms and factors related to chemoresistance in TNBC within the context of EMT, highlighting treatment advancements to improve patients’ outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology, Medical University of Lublin, 1 Chodzki Street, 20-093 Lublin, Poland.
ORCID-Profile: Ewa Błaszczak, Paulina Miziak, Adrian Odrzywolski, Ewelina Gumbarewicz, Andrzej Stepulak
Förderung
- Medical Univeristy of Lublin
- Medical University of Lublin
Zitieren
APA
Błaszczak, E., Miziak, P., Odrzywolski, A., Baran, M., Gumbarewicz, E., & Stepulak, A. (2025). Triple-Negative Breast Cancer Progression and Drug Resistance in the Context of Epithelial–Mesenchymal Transition. Cancers, 17(2), 228. https://doi.org/10.3390/cancers17020228
Vancouver
Błaszczak E, Miziak P, Odrzywolski A, Baran M, Gumbarewicz E, Stepulak A. Triple-Negative Breast Cancer Progression and Drug Resistance in the Context of Epithelial–Mesenchymal Transition. Cancers. 2025;17(2):228. doi:10.3390/cancers17020228
BibTeX
@article{Baszczak2025,
author = {Błaszczak, Ewa and Miziak, Paulina and Odrzywolski, Adrian and Baran, Marzena and Gumbarewicz, Ewelina and Stepulak, Andrzej},
title = {Triple-Negative Breast Cancer Progression and Drug Resistance in the Context of Epithelial–Mesenchymal Transition},
journal = {Cancers},
year = {2025},
volume = {17},
number = {2},
pages = {228},
doi = {10.3390/cancers17020228}
}
EUVIMED